Pre-operative management of a patient with hypoprothrombinemia-lupus anticoagulant syndrome

• References

• 1 Bajaj S, Rapaport S, Fierer D. Amechanism forthe hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61: 684.
• 2 Bajaj S, Rapaport S, Barclay S. et al. Acquired hypoprothrombinemia due to non-neutralizing antibodies to prothrombin: mechanisms and management. Blood 1985; 65: 1538.
• 3 Vinet E, Rich E, Senecal J. Thromboembolism complicating the treatment of lupus anticoagulant hypoprothrombinemia syndrome. J Rheumatol 2006; 33: 2088-2090.
• 4 Vivaldi P, Rossetti G, Galli M. et al. Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. Haematologica 1997; 82: 345-347.
• 5 Colman RW. Hemostasis and Thrombosis: Basic principles in clinical practice. Philadelphia: Williams and Wilkins; 2005. p. 1106.
• 6 Williams S, Linardic C, Wilson O. et al. Acquired hypoprothrombinemia: effects of danazol treatment. Am J Hematol 1996; 53: 272-276.
• 7 Pernod G, Arvieux J, Carpentier PH. et al. Successful treatment of lupus anticoagulant-hypoprothrombinemia syndrome using intravenous immunoglobulins. Thromb Haemost 1997; 78: 969-970.
• 8 Simel D, St. Clair E, Adams J. et al. Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med 1987; 83: 563-566.
• 9 Holm M, Andreasen R, Ingerslev J. Management of bleeding using recombinant factor VIIa in apatient suffering from bleeding tendency due to a lupus anticoagulant-hypoprothrombinemia syndrome. Thromb Haemost 1999; 82: 1776-1778.
• 10 Rituxan full prescribing information. Retrieved February 28, 2007, from http://www.gene.com/gene/products/information/oncology/rituxan/insert.jsp#indications
• 11 Fakhouri F, Vernant JP, Veyradier A. et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: astudy of 11 cases. Blood 2005; 106: 1932-1937.
• 12 Niewold T, Alpert D, Scanzello CR. et al. Rituximabtreatment of thrombotic thrombocytopenicpurpura in the setting of connectivetissue disease. J Rheumatol 2006; 33: 1194-1196.
• 13 Rubenstein E, Arkfeld DG, Metyas S. et al. Rituximab treatment for resistant antiphospholipidsyndrome. J Rheumatol 2006; 33: 355-357.
• 14 Onitilio AA, Skorupa A, Lal A. et al. Rituximab in the treatment of acquired factor VIII inhibitors. Thromb Haemost 2006; 96: 84-87.
• 15 Franchini M, Veneri D, Lippi G. et al. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders. Thromb Haemost 2006; 96: 119-125.
• 16 Peacock N, Levine S. Casereport: Thelupus anticoagulant-hypoprothrombinemia syndrome. Am J Med Sci 1994; 307: 346-349.
• 17 Eberhard A, Sparling C, Sudbury S. et al. Hypoprothrombinemia in childhood systemic lupus erythematosus. Semin Arthritis Rheum 1994; 24: 12-18.
• 18 Khamashta M. Hughes syndrome: Antiprothrombin antibodies. London: Springer-Verlag; 2006. pp. 319-328.
• 19 Cmolik B, Spero JA, Magovern GJ. et al. Redo cardiac surgery: late bleeding complications from topical thrombin induced factor V deficiency. J Thorac Cardiovasc Surg 1993; 105: 222-228.